[Seattle, USA, February 14, 2017]
Landmark study proves that “super-boosting” approach counters negative interaction between key HIV and TB drugs
The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.
[Seattle, USA, February 14, 2017]
April 19-22, 2017
DNDi will be participating at the event.
KEMRI Annual Scientific and Health Conference
February 8-10, 2017
DNDi participated at the event.
Our staff, partners, and stakeholders share their highlights from 2016.
WuXi App Tec [1 December, 2016]
“Harnessing science for the most neglected diseases – A chat with Charles Mowbray, Ph.D., Head of Drug Discovery, DNDi“
The implementation Project for Chagas disease in Colombia is moving forward. After an epidemiological analysis, the partners confirmed the change of the diagnostic algorithm for the country’s pilot projects. With the new algorithm, positive cases for Chagas are confirmed by a simpler procedure test.
devex [18 July, 2016]
“Bringing medicines to the world”
As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing “4-in-1” fixed-dose combinations using the World Health Organization (WHO) recommended treatment regimen for infants and young children. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).
[Paris, France – Le 06 juillet 2016]
La Fondation Mérieux, l’Inserm, l’Institut Pasteur, Réseau CANOPE, MSF, Universcience, le DNDi… Les principaux acteurs français de la lutte contre les maladies infectieuses présentent la série et le webdocumentaire Grandes Tueuses, disponibles en ligne dès maintenant. Conçues comme un outil de sensibilisation pour le grand public et les acteurs de terrain, les 70 vidéos décrivent 14 grandes problématiques de santé publique et sont en open data, en libre accès et libre utilisation. En complément, le webdocumentaire est présenté sur le site d’Allô Docteurs.
The East African [18 June, 2016]
“Easy-to-swallow anti-AIDS drug for East Africa’s children”
European & Developing Countries Clinical Trials Partnership
November 6-9, 2016
DNDi participated in the event.
Daily Monitor [18 June, 2016]
“HIV-positive children get ‘sweet’ ARVs”
Agência Brasil [6 June, 2016]
“Pesquisadores discutem formas de incentivar estudo de doenças negligenciadas” – “Researchers want to encourage the study of neglected diseases”
Pharmaceutical Sciences: Improving World Health
September 5-7, 2016
Steve Robinson, Head of Pharmaceutical Development at DNDi, presented on neglected diseases.
[1 June 2016 – Tokyo, Japan]
Non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) welcomes the G7-related announcement from the Government of Japan to replenish the Global Health Innovative Technology Fund (GHIT Fund) for research and development to combat infectious diseases including neglected tropical diseases.
IP Watch [28 May 2016]
“Reactions to WHA Resolution on R&D financing generally positive”
IP Watch [24 May 2016]
“Global Health R&D Under Debate At World Health Assembly”
21st International AIDS Conference
July 18-22, 2016
Durban, South Africa
DNDi, CHAI, UNITAID, and NEPHAK held an AIDS 2016 Satellite Session to share practical and programmatic experience developing and introducing new paediatric ARV formulations.